NASDAQ:TVTX
Travere Therapeutics, Inc.
Travere Therapeutics, Inc.'s revenue grew 110.5% in fiscal 2025 to $490.7M while operating margin rose to −12.8%, its highest in 10 years. The diluted share count rose 13.1%.Summary generated from Travere Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$490.7M
Revenue growth+110.5%
Revenue, 5-yr CAGR+19.9%
Gross margin97.9%
Operating margin−12.8%
Net margin−5.2%
ROICn/a
Return on equity−29.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+13.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 132 | 109 | 145 | 233 | 491 |
| Operating income | −199 | −320 | −388 | −324 | −63 |
| Net income | −180 | −278 | −111 | −322 | −26 |
| Free cash flow | −20 | −186 | −281 | n/a | n/a |
Recent filings
- 8-KDirector or officer change
Sep 21, 2026 - 4Insider transaction report
Sep 17, 2026 - 4Insider transaction report
Sep 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KDirector or officer change
Jul 9, 2026 - 8-KDirector or officer change
Jun 16, 2026 - 8-KEntry into a material agreement
Jun 2, 2026